BASILEA PHARMACEUTICA: J&J’s Balversa approval set the stage for derazantinib | BUY
BASILEA PHARMACEUTICA - BUY | CHF73 (+64%)J&J’s Balversa approval set the stage for derazantinib
First FGFR kinase inhibitor to gain US approval
Derazantinib will be evaluated in bladder cancer as well this year
Derazantinib’s top-line results in iCCA are expected in H2 2020
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.